Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients

Eva Karam, PharmD, Justin LaPorte, PharmD, Connie Sizemore, PharmD, Xu Zhang, PhD, H. Kent Holland, MD, Melhem Solh, MD, Lawrence E Morris, MD, Asad Bashey, MD PhD, Scott R. Solomon, MD

Blood (2019) 134 (Supplement_1): 3269.

https://doi.org/10.1182/blood-2019-131365

Published: 2019

Journal Articles

Current Graft-Versus-Host Disease (GVHD), Relapse-Free Survival - a Novel, Dynamic Composite Endpoint to Better Define Effectiveness Following Allogenic Hematopoietic Cell Transplantation

Scott R. Solomon, MD, Connie Sizemore, Pharm.D, Michelle Ridgeway, Xu Zhang, PhD, Melhem Solh, MD, Lawrence E. Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2016) 128 (22): 1170.

https://doi.org/10.1182/blood.V128.22.1170.1170

Published: 2016

Journal Articles

Disease Risk and Host Factors, Not Transplant Type, Predict Outcome Following Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia

Scott R. Solomon, MD, Connie Sizemore, Xu Zhang, Katelin Connor, Melhem Solh, MD, H. Kent Holland, MD, Lawrence E. Morris, MD, Asad Bashey, MD PhD

Blood (2015) 126 (23): 4372.

https://doi.org/10.1182/blood.V126.23.4372.4372

Published: 2015

Journal Articles

Disease Risk Index Is the Major Predictor of Outcome Following Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT) and Post-Transplant Cyclophosphamide (PT/Cy)

Scott R. Solomon, MD, Connie Sizemore, Xu Zhang, PhD, Melhem Solh, MD, Lawrence E. Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2015) 126 (23): 2010.

https://doi.org/10.1182/blood.V126.23.2010.2010

Published: 2015

Journal Articles

TBI-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients without Matched Sibling Donors

Scott R. Solomon, MD, Connie Sizemore, PharmD, Xu Zhang, PhD, Stacey Brown, B.A., Katelin Connor, B.S., Lawrence E. Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2014) 124 (21): 426.

https://doi.org/10.1182/blood.V124.21.426.426

Published: 2014

Journal Articles

Corticosteroid-Free Primary Treatment of Chronic Graft-Versus-Host Disease with Rituximab Results in Excellent Responses and Rapid Time to Immunosuppression Discontinuation

Connie Sizemore, PharmD, Michelle Ridgeway, RN, OCN, Xu Zhang, PhD, Stacey Brown, B.A., Lawrence E. Morris, MD, Asad Bashey, MD PhD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2014) 124 (21): 2487.

https://doi.org/10.1182/blood.V124.21.2487.2487

Published: 2014

Journal Articles

Myeloablative Conditioning With PBSC Grafts For T-Replete Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide Results In Universal Engraftment, Low Rates Of Gvhd, NRM and Excellent Survival Outcomes: An Analysis Of Two Consecutive Phase II Studies From a Single Center

Scott R. Solomon, MD, Stephanie Jacobson, FNP-C, OCN, Melissa Sanacore, PharmD, Xu Zhang, PhD, Connie Sizemore, Pharm.D., Stacy Brown, B.A., H. Kent Holland, MD, Lawrence E. Morris, MD, Asad Bashey, MD, PhD

Blood (2013) 122 (21): 3351.

https://doi.org/10.1182/blood.V122.21.3351.3351

Published: 2013

Journal Articles

Outpatient Management of Both Myeloablative and Reduced-Intensity Allogeneic HCT Results in Low Non-Relapse Mortality Irrespective of HCT-CI.

Asad Bashey, MD, PhD, Karen Manion, RN, Lawrence E. Morris, MD, Kent Holland, MD, Gerard Conaghan, MD, Rebekkah Matthews, PharmD, Amy Dooley, PharmD, Connie Sizemore, PharmD, Leslie Kerns, RN, Scott R. Solomon, MD

Blood (2007) 110 (11): 3022.

https://doi.org/10.1182/blood.V110.11.3022.3022

Published: 2007

NARROW

Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients

Current Graft-Versus-Host Disease (GVHD), Relapse-Free Survival - a Novel, Dynamic Composite Endpoint to Better Define Effectiveness Following Allogenic Hematopoietic Cell Transplantation

Disease Risk and Host Factors, Not Transplant Type, Predict Outcome Following Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia

Disease Risk Index Is the Major Predictor of Outcome Following Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT) and Post-Transplant Cyclophosphamide (PT/Cy)

TBI-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients without Matched Sibling Donors

Corticosteroid-Free Primary Treatment of Chronic Graft-Versus-Host Disease with Rituximab Results in Excellent Responses and Rapid Time to Immunosuppression Discontinuation

Outpatient Management of Both Myeloablative and Reduced-Intensity Allogeneic HCT Results in Low Non-Relapse Mortality Irrespective of HCT-CI.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only